Perioperative discontinuation of SGLT2-inhibitors and cardiac complications after noncardiac surgery: secondary analysis of two prospective observational cohort studies

This study investigates whether the perioperative discontinuation of sodium-glucose cotransporter-2 inhibitors (SGLT2i) increases the risk of cardiovascular complications following noncardiac surgery. The findings indicate that stopping SGLT2i is associated with a significantly higher incidence of cardiac events within 90 days post-surgery, challenging current clinical guidelines that recommend discontinuation to prevent euglycemic diabetic ketoacidosis. The authors call for randomized controlled trials to further explore these implications.